Rouvax

BIOLOGICAL3 trials

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France, Bavarian Nordic, GlaxoSmithKline

Conditions

Atopic DermatitisMalariaMeasles

Phase 2

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

CompletedNCT00891007

Bavarian NordicMeasles

Start: 2009-06-30End: 2010-08-31Updated: 2012-07-27

Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

CompletedNCT01231503

GlaxoSmithKlineMalaria

Start: 2011-01-13End: 2014-12-23Updated: 2018-08-15

Unknown Phase

IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis

CompletedNCT00820820

Institut National de la Santé Et de la Recherche Médicale, FranceAtopic Dermatitis

Start: 2009-01-09End: 2012-03-26Updated: 2026-03-13